President & CEO
Marc Forth has served as our Chief Executive Officer since May 2019. Prior to AEON Biopharma, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology Division. During his 16 year tenure at Allergan, Mr. Forth was responsible for all aspects of the commercialization of both current and future products within Neurosciences, Urology and Medical Dermatology, most notably Botox® for all therapeutic uses. Prior to Allergan, Mr. Forth held various Sales and Marketing roles of increasing responsibility at TAP Pharmaceutical Inc., a specialty company focused on Urology, Oncology, Gynecology and Gastroenterology. Mr. Forth received a B.S. in Business Administration from California State University, Fresno and a Graduate Marketing Certification from Southern Methodist University.
Chris Carr has served as our Chief Financial Officer since September 2019. Prior to AEON Biopharma, Mr. Carr served on the board of directors and as Chief Financial Officer and Executive Vice President of Finance and Information Technology of Dendreon Pharmaceuticals LLC. Prior to Dendreon, Mr. Carr was at Abbott Laboratories, Inc., where he served as Controller and Senior Director of Greater China Nutrition, as Controller and Director of Global Commercial Finance, as Vice President of the Finance Refractive Division, and as Director of Finance R&D and Business Development. Mr. Carr previously held escalating senior finance roles with PerkinElmer, Inc. and Genzyme Corporation. Mr. Carr received a B.S. in Finance and Economics from Boston College.
Del Stagg, PhD
Vice President, Technical Operations & Regulatory
Del Stagg has served as our Vice President, Development & Regulatory since June 2019. Mr. Stagg provides AEON Biopharma with over 40 years of global biopharma, medical product development and regulatory affairs experience. Mr. Stagg has been responsible for U.S. and international marketing approvals for several biologics, including therapeutic and aesthetic indications for Botox® and the aesthetic indication for Jeuveau®. Mr. Stagg drove significant value during his tenure in the research and development group at Allergan, Inc. and has served inmanagement roles of several medical product companies, including Evolus, Inc. Mr. Stagg received his PhD in Physiology and Pharmacology from Duke University.
Scott Akamine has served as our General Counsel and Corporate Secretary since August 2019. Prior to AEON Biopharma, he served as Vice President, Associate General Counsel at CoreLogic, Inc. where he had legal responsibility for U.S. and international business development transactions, including acquisitions and partnerships, as well as corporate governance and public company securities law compliance. Prior to CoreLogic, he served as General Counsel and Secretary at Incipio, LLC, where he oversaw all legal, compliance, human resources and administrative functions for the company. Mr. Akamine previously served as Senior Counsel and Assistant Secretary at Allergan, Inc. where he had legal responsibility for business development transactions, corporate governance matters, public company securities lawcompliance and activism defense, providing legal counsel through the hostile defense and sale to Actavis plc in 2015. Prior to Allergan, Mr. Akamine was a corporate attorney at Latham & Watkins LLP. Mr. Akamine earned a B.A. in Legal Studies from the Chapman University and a J.D. from Pepperdine University School of Law.
Interested in AEON BioPharma?
Learn more about us and our breakthrough toxin therapy treatment.